Phase II open-label, sequential cohort, dose-escalation study of BMN 111 in children with achondroplasia
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Vosoritide (Primary)
- Indications Achondroplasia
- Focus Adverse reactions; Proof of concept
- Acronyms ACH
- Sponsors BioMarin Pharmaceutical
- 19 May 2017 Planned End Date changed from 1 Jan 2019 to 1 Dec 2017.
- 19 May 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2017.
- 19 May 2017 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History